Spyre Therapeutics Launches $350 Million Stock Offering Underwritten by Jefferies, TD, Leerink, Stifel
Spyre Therapeutics announced a $350 million stock offering of 4.1 million shares at $85 each, with underwriters having a 30-day option for additional shares. Proceeds will fund gastroenterology, rheumatology, and dermatology programs, and advance SPY072 for hidradenitis suppurativa. Closing is expected October 7, 2026, according to the company.
How this was made
The 30-second read
Why it matters
The $350 million raise is a material corporate action that can affect share price and valuation.
Market read
Primary disclosure of a large equity raise; traders should assess dilution impact.
What to watch
Underwriters' option to purchase additional shares could increase dilution further
Background
Spyre Therapeutics is a clinical‑stage biotech focusing on GI, rheumatology, and dermatology indications.
Ticker impact
Spyre Therapeutics announced a $350 million public stock offering at $85 per share, the first disclosure of this capital raise.
likely downward pressure as the market prices in dilution
Large primary offering disclosed for the first time; market typically reacts negatively to dilution.
Market effects
Provides funding for biotech pipeline, may boost sector sentiment if trials succeed
US biotech market sees new capital inflow
Limited to biotech investors
Counterpoint
The raise could fund breakthrough trials, offering upside if data are positive
Key entities
- companySpyre Therapeutics
Biotech firm issuing new shares
- underwriterJefferies
Lead underwriter for the offering
